Evercore Upgrades Revolution Medicines (NASDAQ:RVMD) to “Strong-Buy”

Revolution Medicines (NASDAQ:RVMD) was upgraded by research analysts at Evercore to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

RVMD has been the topic of a number of other research reports. HC Wainwright upped their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. raised their target price on Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. UBS Group raised Revolution Medicines to a “strong-buy” rating in a research report on Thursday, December 4th. Wolfe Research initiated coverage on Revolution Medicines in a report on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines Stock Down 1.1%

Revolution Medicines stock opened at $102.15 on Wednesday. The business has a fifty day moving average price of $98.72 and a 200-day moving average price of $69.89. Revolution Medicines has a 1-year low of $29.17 and a 1-year high of $124.49. The stock has a market capitalization of $19.75 billion, a price-to-earnings ratio of -17.28 and a beta of 1.01. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the firm posted ($1.12) earnings per share. Equities research analysts forecast that Revolution Medicines will post -3.49 EPS for the current fiscal year.

Insider Activity

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 5,447 shares of Revolution Medicines stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $418,438.54. Following the completion of the transaction, the insider owned 278,600 shares of the company’s stock, valued at approximately $21,402,052. The trade was a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark A. Goldsmith sold 15,394 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total transaction of $1,182,567.08. Following the completion of the transaction, the insider owned 232,469 shares of the company’s stock, valued at approximately $17,858,268.58. This trade represents a 6.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 113,792 shares of company stock valued at $10,734,640 in the last quarter. Company insiders own 8.20% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. increased its position in shares of Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after buying an additional 125 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Revolution Medicines by 0.4% during the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock valued at $2,566,000 after buying an additional 130 shares in the last quarter. Signaturefd LLC grew its stake in Revolution Medicines by 33.1% in the 4th quarter. Signaturefd LLC now owns 656 shares of the company’s stock valued at $52,000 after acquiring an additional 163 shares during the period. Allworth Financial LP raised its position in Revolution Medicines by 57.2% during the fourth quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after acquiring an additional 210 shares during the period. Finally, Farther Finance Advisors LLC raised its position in Revolution Medicines by 44.7% during the fourth quarter. Farther Finance Advisors LLC now owns 751 shares of the company’s stock worth $60,000 after acquiring an additional 232 shares during the period. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Evercore upgraded RVMD to “strong-buy,” signaling institutional confidence that the company’s RAS-focused programs could justify higher valuation. Read More.
• Positive Sentiment: Corporate update: Revolution said it is advancing late-stage RAS pipeline studies (progress that could drive long-term revenue potential if pivotal data are positive). Read More.
• Positive Sentiment: Media/analysis pieces are highlighting potential clinical breakthroughs in RVMD’s cancer programs, which can create upside if follow-up data confirm efficacy. Read More.
• Neutral Sentiment: Management participated in earnings commentary and the TD Cowen healthcare conference, providing additional investor access to program timelines and readouts (useful for roadmapping catalysts but not immediate stock-moving data). Read More.
• Neutral Sentiment: Earnings call transcript is available for detail on trial timing, enrollment and strategy — good for investors who want granular color on pipeline milestones. Read More.
• Negative Sentiment: Q4 results missed expectations: RVMD reported a ($1.86) EPS vs. consensus ($1.56), a wider loss versus the prior year — a near-term negative for sentiment. Read More.
• Negative Sentiment: Raised 2026 operating expense outlook to $1.6B–$1.7B to fund late‑stage RAS studies, meaning significantly higher cash burn and dilution risk before commercialization. This guidance is a key driver of the negative market reaction today. Read More.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.